Gilham DE - Search Results

1

Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.

Waddington SN, Crossley R, Sheard V, Howe SJ, Buckley SM, Coughlan L, Gilham DE, Hawkins RE, McKay TR. Waddington SN, et al. Among authors: gilham de. Mol Ther. 2010 Dec;18(12):2104-11. doi: 10.1038/mt.2010.174. Epub 2010 Aug 24. Mol Ther. 2010. PMID: 20736928 Free PMC article.

2

Antibodies: from genes to targeted cancer gene therapy.

Hawkins RE, Whittington HA, Watkins SJ, Gilham DE. Hawkins RE, et al. Among authors: gilham de. Gene Ther. 1998 Dec;5(12):1581-3. doi: 10.1038/sj.gt.3300788. Gene Ther. 1998. PMID: 10023436 No abstract available.

3

Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.

Eaton D, Gilham DE, O'Neill A, Hawkins RE. Eaton D, et al. Among authors: gilham de. Gene Ther. 2002 Apr;9(8):527-35. doi: 10.1038/sj.gt.3301685. Gene Ther. 2002. PMID: 11948378

4

Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.

Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE. Gilham DE, et al. J Immunother. 2002 Mar-Apr;25(2):139-51. doi: 10.1097/00002371-200203000-00002. J Immunother. 2002. PMID: 12074044

5

T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches.

Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE. Sheen AJ, et al. Among authors: gilham de. Br J Cancer. 2003 Apr 7;88(7):1119-27. doi: 10.1038/sj.bjc.6600857. Br J Cancer. 2003. PMID: 12671714 Free PMC article.

6

Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.

Thistlethwaite F, Mansoor W, Gilham DE, Hawkins RE. Thistlethwaite F, et al. Among authors: gilham de. Curr Opin Mol Ther. 2005 Feb;7(1):48-55. Curr Opin Mol Ther. 2005. PMID: 15732529 Review.

7

Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.

Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE. Cheadle EJ, et al. Among authors: gilham de. Br J Haematol. 2005 May;129(3):322-32. doi: 10.1111/j.1365-2141.2005.05456.x. Br J Haematol. 2005. PMID: 15842655 Free article.

8

Engineering T cells for cancer therapy.

Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Mansoor W, et al. Among authors: gilham de. Br J Cancer. 2005 Nov 14;93(10):1085-91. doi: 10.1038/sj.bjc.6602839. Br J Cancer. 2005. PMID: 16251873 Free PMC article. Review.

9

Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.

Jiang HR, Gilham DE, Mulryan K, Kirillova N, Hawkins RE, Stern PL. Jiang HR, et al. Among authors: gilham de. J Immunol. 2006 Oct 1;177(7):4288-98. doi: 10.4049/jimmunol.177.7.4288. J Immunol. 2006. PMID: 16982863

10

Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK.

Thistlethwaite FC, Gilham DE, Hawkins RE. Thistlethwaite FC, et al. Among authors: gilham de. Cancer Immunol Immunother. 2007 Jun;56(6):939-42. doi: 10.1007/s00262-007-0301-8. Epub 2007 Feb 27. Cancer Immunol Immunother. 2007. PMID: 17333180 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page